Zivo Bioscience

Zivo Bioscience, Inc. engages in the study, development, and commercialization of natural nutritional compounds and bioactive molecules. It offers proprietary algae strain, extracts and supernatants, and bioactive compounds. The company was founded by Howard R. Baer on March 28, 1983 and is headquartered in Keego Harbor, MI.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Zivo Bioscience, Inc. engages in the study, development, and commercialization of natural nutritional compounds and bioactive molecules. It offers proprietary algae strain, extracts and supernatants, and bioactive compounds. The company was founded by Howard R. Baer on March 28, 1983 and is headquartered in Bloomfield Hills, MI.

ZIVO Bioscience (ZIVO) stock is rocketing higher on Friday despite no news concerning the company in what appears to be a pump and dump. The post ZIVO Stock: 6 Things to Know About Biotech ZIVO Bioscience as Shares Rocket on No News appeared first on InvestorPlace.

ZIVO Stock: 6 Things to Know About Biotech ZIVO Bioscience as Shares Rocket on No News

The stock price of Zivo Bioscience Inc (NASDAQ: ZIVO) increased by over 90% during intraday trading this morning. This is why it happened.

ZIVO Stock: Why It Substantially Increased Today

Zivo Bioscience (ZIVO) stock is rocketing higher on Monday with heavy trading despite a lack of news coming from the company today. The post ZIVO Stock: 8 Things to Know About Biotech Play Zivo Bioscience as Shares Rocket 155%+ appeared first on InvestorPlace.

ZIVO Stock: 8 Things to Know About Biotech Play Zivo Bioscience as Shares Rocket 155%+

The stock price of Zivo Bioscience Inc (NASDAQ: ZIVO) increased by over 100% pre-market today. These are the details.

ZIVO Stock Price Surges Over 100% Pre-Market

KEEGO HARBOR, Mich., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Zivo Bioscience, Inc. (NASDAQ: ZIVO, ZIVOW) (“ZIVO” and the “Company”), a biotech/agtech R&D company engaged in the development and commercialization of therapeutic, medicinal and nutritional product candidates originally derived from proprietary algal cultures, today issues a letter to shareholders from Chief Executive Officer Andrew Dahl.

Zivo Bioscience, Inc. Issues Letter to Shareholders

Keego Harbor, Michigan--(Newsfile Corp. - August 11, 2021) - ZIVO Bioscience (NASDAQ: ZIVO) today announced that Andrew Dahl will be attending the Q3 Virtual Investor Summit.  Event Q3 Investor Summit Date August 17-18th, 2021 Presentation August 17th at 9:30am ET&#

ZIVO Bioscience to Present at the Q3 Virtual Investor Summit

KEEGO HARBOR, Mich., July 02, 2021 (GLOBE NEWSWIRE) -- Zivo Bioscience, Inc. (NASDAQ: ZIVO, ZIVOW) (“ZIVO” and the “Company”), a biotech/agtech R&D company engaged in the development and commercialization of therapeutic, medicinal and nutritional product candidates originally derived from proprietary algal cultures, today announced the closing of the sale of an additional 150,000 shares of common stock, at a price to the public of $4.99 per share less underwriting discounts and commissions, pursuant to the partial exercise of the underwriters' over-allotment option in connection with its previously announced public offering that closed on June 2, 2021. ZIVO received gross proceeds of approximately $748,500, before deducting underwriting discounts and commissions and other estimated offering expenses.

Zivo Bioscience, Inc. Announces Closing of Underwriters' Partial Exercise of Over-Allotment Option in Connection with its Previously Announced Public Offering

KEEGO HARBOR, Mich., June 02, 2021 (GLOBE NEWSWIRE) -- ZIVO Bioscience, Inc. (NASDAQ:ZIVO), a biotech/agtech R&D company engaged in the development and commercialization of therapeutic, medicinal and nutritional bioproduct candidates originally derived from proprietary algal cultures, today announced that President & Chief Executive Officer Andrew Dahl will present a corporate overview at the three-day LD Micro Virtual Invitational Conference being held on June 8 – 10, 2021.

ZIVO Bioscience to Present at the LD Micro Virtual Invitational Conference on June 9, 2021

KEEGO HARBOR, Mich., June 02, 2021 (GLOBE NEWSWIRE) -- Zivo Bioscience, Inc. (NASDAQ: ZIVO, ZIVOW) (“ZIVO” and the “Company”), a biotech/agtech R&D company engaged in the development and commercialization of therapeutic, medicinal and nutritional product candidates originally derived from proprietary algal cultures, today announced the closing of its previously announced underwritten public offering of 2,760,000 units at a price to the public of $5.00 per unit. Each unit issued in the offering consisted of one share of common stock and one warrant to purchase one share of common stock at an exercise price of $5.50. The common stock and warrants were immediately separable and were issued separately. The common stock and warrants began trading on the Nasdaq Capital Market on May 28, 2021, under the symbols "ZIVO" and "ZIVOW," respectively. ZIVO received gross proceeds of approximately $13.8 million, before deducting underwriting discounts and commissions and other estimated offering expenses. All share numbers and pricing information in this press release reflect the Company's previously announced 1-for-80 reverse stock split of its issued and outstanding common stock, which became effective at 12:01 a.m., Eastern Time, on May 28, 2021.

Zivo Bioscience, Inc. Announces Closing of Upsized $13.8 Million Public Offering and Uplisting to Nasdaq

KEEGO HARBOR, Mich., May 27, 2021 (GLOBE NEWSWIRE) -- Zivo Bioscience, Inc. (OTCMKTS:ZIVO) a biotech/agtech R&D company engaged in the development and commercialization of nutritional/nutraceutical product candidates originally derived from proprietary algal cultures, today announced the pricing of its upsized underwritten public offering of 2,760,000 units at a price to the public of $5.00 per unit. Each unit to be issued in the offering consists of one share of common stock and one warrant to purchase one share of common stock at an exercise price of $5.50. The common stock and warrants are immediately separable and will be issued separately. The common stock and warrants are expected to begin trading on the Nasdaq Capital Market, on May 28, 2021, under the symbols “ZIVO” and “ZIVOW,” respectively. ZIVO expects to receive gross proceeds of $13.8 million, before deducting underwriting discounts and commissions and other estimated offering expenses. In connection with the offering, the Company will effectuate a reverse split of its issued and outstanding common stock at a ratio of 1-for-80. The reverse stock split is expected to be effective at 12:01 a.m., Eastern Time, on May 28, 2021. The share numbers and pricing information in this release are adjusted to give effect to the reverse stock split.

Zivo Bioscience, Inc. Announces Pricing of Upsized $13.8 Million Public Offering and Up-listing to Nasdaq

KEEGO HARBOR, Mich., April 26, 2021 (GLOBE NEWSWIRE) -- ZIVO Bioscience, Inc. (OTCMKTS:ZIVO) a biotech/agtech R&D company engaged in the development and commercialization of nutritional/nutraceutical product candidates originally derived from proprietary algal cultures, announces today the US Patent Office has issued a Notice of Allowance for the use of the company's proprietary algal biomass product to promote a healthy immune response for use in dairy cattle. Follow-on patent filings for other animal species and humans are in process.

ZIVO Bioscience Announces US Patent Office Notice of Allowance for Administration of Proprietary Algal Biomass to Support Immune Health

KEEGO HARBOR, Mich., March 11, 2021 (GLOBE NEWSWIRE) -- ZIVO Bioscience, Inc. (OTCQB: ZIVO), a biotech/agtech R&D company engaged in the development and commercialization of therapeutic and additive product candidates originally derived from proprietary algal cultures, announces that CEO Andrew A. Dahl will present at Maxim Group's Inaugural Emerging Growth Virtual Conference to be held March 17-18, 2021.

ZIVO Bioscience to Participate in Maxim Group's Inaugural Emerging Growth Virtual Conference

KEEGO HARBOR, MI / ACCESSWIRE / January 11, 2021 / ZIVO Bioscience, Inc. (OTCQB:ZIVO) a biotech/agtech R&D company engaged in the development and commercialization of therapeutic/additive product candidates originally derived from proprietary algal cultures, announces today that in its recent analysis of two poultry studies performed at separate research facilities, ZIVO product candidates provided statistically significant feed conversion benefits in healthy broiler flocks exposed to pathogens present in litter from previous flocks, emulating exposure that may occur in a typical broiler production environment. ZIVO has been developing a product candidate designed to boost immune response and combatting a broad range of infective pathogens, with the goal of improving feed conversion and productivity to provide cost-savings for poultry producers.

ZIVO Bioscience Successfully Confirms Poultry Growth Promotion and Feed Conversion Ratio Improvements in Typical Production Environments

KEEGO HARBOR, MI / ACCESSWIRE / January 7, 2021 / ZIVO Bioscience, Inc. (OTCMQB:ZIVO) a biotech/agtech R&D company engaged in the development and commercialization of therapeutic, food and feed additive products announced today that Keith R. Marchiando joined the Company's as Chief Financial Officer, Treasurer, and Secretary, effective January 1, 2021.

Zivo Bioscience Names Keith R. Marchiando as Chief Financial Officer

News for Zivo Bioscience Stock (ZIVO)